About
Ophthalmology Gene Therapy
Areas of Focus
Categories
Gene Therapy, RNA & Peptide TherapyNorth & South Carolina
Clinical Trials (2)
View allTotal Trials
2
As Lead Sponsor
2
As Collaborator
0
Total Enrollment
25
By Phase
PHASE1/PHASE2: 2
By Status
RECRUITING: 2
Clinical Trials Pipeline2 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Today
Hover over trial bars to see details
Recent Trials
NCT07185256Lead Sponsor
Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)
PHASE1/PHASE2Recruiting
10 participants
Started: Sep 30, 2025 · Completed: Aug 31, 2030
NCT05616793Lead Sponsor
Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD)
PHASE1/PHASE2Recruiting
15 participants
Started: Jun 15, 2023 · Completed: Jun 15, 2028
Locations (1)
Headquarters
Raleigh, NC, United States
Map
Loading map...